A two-part study to evaluate the safety, tolerability, and pharmacokinetics of single and repeat oral doses of GSK557296 in a randomized, single-blind, placebo-controlled, dose-rising design, and to evaluate the effect of food on single oral doses of GSK557296 in healthy adult subjects.
Phase of Trial: Phase I
Latest Information Update: 16 Mar 2012
At a glance
- Drugs Epelsiban (Primary)
- Indications Premature ejaculation
- Focus Adverse reactions
- Sponsors GlaxoSmithKline
- 12 Oct 2008 Status changed from not yet recruiting to completed as reported by ClinicalTrials.gov.
- 07 Nov 2007 New trial record.